Paul M O'Byrne

Mar 9, 2023 | erj.ersjournals.com | Paul M O'Byrne |Gauvreau GM |O'Byrne PM |Boulet LP

ProceduresEcleralimab is formulated as a PulmoSol engineered powder in hard capsules and delivered to the lungs via a Breezhaler dry powder inhaler device, all provided by Novartis (Basel, Switzerland). Based on clinical and nonclinical safety data, a starting dose of 4 mg administered once daily for 12 weeks was expected to provide adequate pulmonary exposure to assess pharmacodynamic effects against allergen-induced airway responses.